← Every applicant
Invagen Pharms FDA Approvals
15 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| EMPAGLIFLOZINNew drugSep 22, 2026TABLET, ORAL |
| RIVAROXABANNew drugFeb 20, 2026TABLET, ORAL |
| RIVAROXABANNew drugMay 14, 2025TABLET, ORAL |
| TICAGRELORNew drugMay 5, 2025TABLET, ORAL |
| LINAGLIPTINNew drugSep 3, 2024TABLET, ORAL |
| SEVELAMER CARBONATENew drugJul 12, 2024FOR SUSPENSION, ORAL |
| LANREOTIDE ACETATENew drugMay 21, 2024SOLUTION, SUBCUTANEOUS |
| OSELTAMIVIR PHOSPHATENew drugOct 3, 2023CAPSULE, ORAL |
| MECLIZINE HYDROCHLORIDENew drugFeb 17, 2022TABLET, CHEWABLE, ORAL |
| MECLIZINE HYDROCHLORIDENew drugFeb 17, 2022TABLET, ORAL |
| LANTHANUM CARBONATENew drugJan 24, 2022TABLET, CHEWABLE, ORAL |
| LANREOTIDE ACETATENew drugDec 17, 2021SOLUTION, SUBCUTANEOUS |
| OSELTAMIVIR PHOSPHATENew drugAug 30, 2021FOR SUSPENSION, ORAL |
| PENICILLAMINENew drugAug 19, 2021CAPSULE, ORAL |
| VILAZODONE HYDROCHLORIDENew drugApr 7, 2021TABLET, ORAL |